- VivaMed BioPharma has partnered with Syngene International to integrate AI-powered discovery with expanded preclinical validation capabilities.
- The collaboration aims to deliver scientifically validated and partner-ready therapeutic programs.
VivaMed BioPharma has entered into a collaboration with Syngene International, a contract research development and manufacturing organization (CRDMO), to strengthen its AI-powered drug discovery and validation infrastructure. The partnership is designed to integrate VivaMed’s AI-derived therapeutic hypotheses with Syngene’s preclinical development capabilities.
VivaMed, a clinical-stage pharmaceutical company, applies artificial intelligence to discover and advance repurposed and improved therapeutic assets. Under the agreement, Syngene will support the validation of these programs through preclinical development services. The stated goal is to generate scientifically validated and partner-ready therapeutic programs.
According to the companies, the collaboration is built around three pillars. The first is AI-powered discovery, which incorporates VivaMed’s proprietary AI engine supported by a global network of co-scientists. The second pillar focuses on rigorous validation, including in-vitro and in-vivo pharmacology studies, biomarker confirmation, and assay development. The third pillar centers on strategic commercialization aligned with pharmaceutical partner priorities to create de-risked and scalable development opportunities.
“AI-driven discovery must be matched with rigorous experimental execution. It ensures that our most promising programs are developed with the scientific depth and operational discipline required.”
Kendric Speagle, CEO of VivaMed.
VivaMed stated that it intends to continue expanding its network of research, validation, and commercialization collaborators. The company is seeking additional relationships with contract research organizations, academic institutions, and pharmaceutical partners to further support its development strategy.
